Evidence map›Paper›PMID 36741028›Full record

ArticleFrontiers in oncology2023

Glutamine synthetase expression rescues human dendritic cell survival in a glutamine-deprived environment.

Robert Schoeppe, Nathalie Babl, Sonja-Maria Decking, Gabriele Schönhammer, Andreas Siegmund, Christina Bruss, Katja Dettmer, Peter J Oefner, Linus Frick, Anna Weigert and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Modulating glutamate neurotransmission inFrontiers in immunology · 2026
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Robert SchoeppeDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Nathalie BablDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Sonja-Maria DeckingDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Gabriele SchönhammerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Andreas SiegmundDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Christina BrussDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Katja DettmerInstitute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Peter J OefnerInstitute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Linus FrickInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg and University of Regensburg, Regensburg, Germany.
Anna WeigertInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg and University of Regensburg, Regensburg, Germany.
Jonathan JantschInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg and University of Regensburg, Regensburg, Germany.
Wolfgang HerrDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Michael RehliDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Kathrin RennerDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Marina KreutzDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glutamine deficiency is a well-known feature of the tumor environment. Here we analyzed the impact of glutamine deprivation on human myeloid cell survival and function. Methods: Different types of myeloid cells were cultured in the absence or presence of glutamine and/or with L-methionine-S-sulfoximine (MSO), an irreversible glutamine synthetase (GS) inhibitor. GS expression was analyzed on mRNA and protein level. GS activity and the conversion of glutamate to glutamine by myeloid cells was followed by 13C tracing analyses. Results: The absence of extracellular glutamine only slightly affected postmitotic human monocyte to dendritic cell (DC) differentiation, function and survival. Similar results were obtained for monocyte-derived macrophages. In contrast, proliferation of the monocytic leukemia cell line THP-1 was significantly suppressed. While macrophages exhibited high constitutive GS expression, glutamine deprivation induced GS in DC and THP-1. Accordingly, proliferation of THP-1 was rescued by addition of the GS substrate glutamate and 13C tracing analyses revealed conversion of glutamate to glutamine. Supplementation with the GS inhibitor MSO reduced the survival of DC and macrophages and counteracted the proliferation rescue of THP-1 by glutamate. Discussion: Our results show that GS supports myeloid cell survival in a glutamine poor environment. Notably, in addition to suppressing proliferation and survival of tumor cells, the blockade of GS also targets immune cells such as DCs and macrophages.

Indexed as

dendritic cellsglutamateglutamineglutamine synthetasemacrophages

Identifiers

PMID36741028
PMCPMC9894315
OpenAlexW4317388433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.